CTIS2024-510923-20-00Active, not recruitingPhase 1
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis - MK-6024-017
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 91
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •Has a diagnosis of compensated cirrhosis secondary to metabolic dysfunction-associated steatohepatitis (MASH) based on histology (nonalcoholic steatohepatitis Clinical Research Network [NASH CRN] criteria) or non-histological criteria based on protocol specified serum and imaging biomarkers., Has no history of type 2 diabetes mellitus (T2DM) or has a history of T2DM with a glycated hemoglobin (A1C) =9% and the T2DM is controlled by diet or stable doses of antihyperglycemic agents (AHAs)., Is of any sex/gender, from 18 years to 80 years of age inclusive., A participant assigned female sex at birth is eligible to participate if not pregnant or breastfeeding, and Is either not a participant/participants of childbearing potential (POCBP) or is a POCBP and the following applies: uses a contraceptive method that is highly effective, has a negative highly sensitive pregnancy test, abstains from breastfeeding during the study intervention period and for at least 5 weeks after the last dose of study intervention, their medical history, menstrual history, and recent sexual activity have been reviewed by the investigator.
Exclusion Criteria
- •Has a history or evidence of chronic liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD) or MASH., Has human immunodeficiency virus (HIV), as assessed by medical history or by current use of HIV antiretroviral therapy., Has hyperthyroidism or inadequately controlled hypothyroidism., Has a history of glucagonoma., Has a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2., Has significant systemic or major illnesses, including recent (=6 months before Visit 1a/Screening) onset of events of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or transient ischemic attack., Has a history of pathologic, symptomatic, or sustained tachyarrhythmia., Has a history of malignancy =5 years before Visit 1a/Screening, except for squamous or basal cell carcinomas of the skin and any in situ carcinomas, excluding in situ carcinoma of the bladder., Has undergone a major surgery (e.g, requiring general anesthesia) =3 months before Visit 1a/Screening, or has not fully recovered from surgery, or has major surgery planned during the participation of the current study., Has a history of organ transplantation, except for corneal transplant., Has received blood products =2 months before Visit 1a/Screening, and/or donated blood products =1 month before Visit 1a/Screening, and/or plans to donate blood products throughout the duration of the study., Has history of decompensated liver disease., Has a current diagnosis of end-stage renal disease and is receiving dialysis., Has known allergies, hypersensitivity, contraindication, or intolerance to the active ingredients and/or excipients of efinopegdutide., Has been treated with any protocol prohibited agents., Has previous or current use of prescription weight-management medications., Has been treated with pharmacologic doses of systemic corticosteroid medication., Is currently on treatment with an antihypertensive therapy that is not a stable dose for at least 3 months before Visit 1a/Screening., Is currently on treatment with an antihyperlipidemic therapy that is not a stable dose for at least 3 months before Visit 1a/Screening and through Visit 3/Randomization, Is currently participating in or has participated in an interventional clinical study and received an investigational compound or used an investigational device =3 months before participating in this study., Has a clinically significant electrocardiogram (ECG) abnormality that requires further diagnostic evaluation or intervention., Has developed a new medical condition, experienced a change in the status of an existing medical condition, developed a laboratory abnormality, or required a new treatment or medication during the Screening period that satisfies any of the study exclusion criteria., Has a baseline model for end-stage liver disease – sodium (MELD-Na) score =12 at Visit 1a/Screening, Has a previous or current history of significant alcohol consumption for a period of more than 3 consecutive months within the 24 months before Visit 1a/Screening or has an inability to reliably quantify alcohol consumption., Has a recent history (defined as =3 years) of drug abuse or is a current user of recreational or illicit drugs (per local regulations) at the time of Visit 1a/Screening., Has (or caregiver has) limitations that would prevent administration of the study intervention via injection, after receiving ins
Investigators
Similar Trials
Not yet recruiting
Phase 2
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell DiseaseHaematological DisordersPACTR202206488890527Bausch Health America60
Completed
Phase 2
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell DiseaseSickle Cell Disease patients with history of VOCsAnemia, Hemolytic, Congenital, Hematologic Diseases,LBCTR2022095104Bausch Health LLC9
Active, not recruiting
Phase 1
A clinical trial of MK-1654 in healthy volunteers.Respiratory Syncytial Virus InfectionEUCTR2018-003347-28-GBMerck Sharp & Dohme Corp90
Active, not recruiting
Phase 1
This is a trial that is studying a new inhaled medicine, MDT-637, that is being researched for the treatment of a viral infection of the lungs that typically affects the young and the elderly (Respiratory Syncytial Virus, RSV). Adult volunteers will be infected with RSV (the infection is typically mild in adults), half of these volunteers will be treated with MDT-637, and the other half will receive placebo which has no effect on RSV.EUCTR2012-001107-20-GBMicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd.143
Recruiting
Phase 2
Study to Assess the Effectiveness and Safety of AZD4604 in Adult Patients with Uncontrolled Moderate-to-Severe Asthma – The AJAX StudyCTRI/2024/04/065120AstraZeneca AB